Insider Purchases: Inside the Buy

Tag: Stock Analysis 2026

Split image showing Corcept Therapeutics stock volatility: one side with a red falling chart and FDA rejection stamp, the other with a green rising chart and glowing biotech lab vial, symbolizing high-risk, high-reward biotech investing.

CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?

Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.

Read entire article

Split-screen illustration of The Trade Desk (TTD) stock falling sharply from prior highs, contrasted with a bold “$148M insider buy” stamp next to a founder silhouette, with small Connected TV and open-internet advertising icons in the background.

TTD Stock Analysis 2026: Jeff Green’s $148M Bet — Is The Trade Desk the Ultimate “Buy the Dip” Play?

The Trade Desk just got the loudest kind of bullish signal: the founder-CEO bought $148M of his own stock after an 80%+ drawdown. Institutions are stacked, shorts are circling, and valuation has finally cooled from “bubble” to “business.” The question now: is TTD a generational dip… or a beautiful trap?

Read entire article

A futuristic enterprise dashboard resembling a control tower, with AI workflow nodes and automated ticketing visuals, symbolizing ServiceNow as an AI control platform.

NOW Stock Analysis 2026: Bill McDermott’s $3M “Strong Buy” Signal — Is ServiceNow the AI Control Tower?

ServiceNow (NOW) is fighting a valuation reset with AI-powered fundamentals. CEO Bill McDermott just made a rare $3M insider buy — a signal worth decoding.

Read entire article

A payment terminal and a rocket launching side by side, symbolizing Shift4’s fintech growth potential and high volatility battleground stock status.

FOUR Stock Analysis 2026: Is Shift4 a Payments Powerhouse or a Falling Knife?

Shift4 (FOUR) is a full-blown battleground stock. Founder buying, 35% short interest, heavy institutional ownership, and a forward P/E near 7. Rocket fuel — or engine trouble?

Read entire article